Remepy said it raised $36 million in Series A funding to expand its pipeline of drug-software combination treatments and support a planned Phase III trial of its lead Parkinson’s disease program.
The round was led by O.G. Venture Partners and M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany. Existing and new investors also participated, including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group and IT-Farm Corp.
The company said the new funding brings its total capital raised to $62 million.
Remepy is developing what it calls Hybrid Drugs, treatments that combine prescription medications with personalized, AI-driven therapeutic apps. The company said the approach is designed to pair pharmacological treatment with adaptive physical, cognitive and behavioral interventions through a standard prescription model.
Michal Tsur and Or Shoval, Remepy’s co-CEOs
(Photo: Nati Gold)
The funding will be used to expand Remepy’s pharmaceutical co-development partnerships, advance its pipeline and platform, and fund global Phase III development of Hybridopa, its lead program for Parkinson’s disease. The trial is expected to begin in the fourth quarter of 2026. Hybridopa is still investigational and has not been approved by the U.S. Food and Drug Administration.
The company said Hybridopa produced encouraging Phase IIa results, showing improvement in both motor and non-motor symptoms in Parkinson’s patients. Remepy said the results were supported by peer-reviewed publications examining the biological mechanisms behind the treatment’s clinical effect.
Remepy recently announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, to develop Hybrid Drugs across several indications, beginning with rare tumors.
The team at Remepy
(Photo: Nati Gold)
“We believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient,” Michal Tsur and Or Shoval, Remepy’s co-CEOs, said in a statement. “Over the past year, we’ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment and partnerships with leading pharmaceutical companies. This financing allows us to advance Phase III of Hybridopa for Parkinson’s disease, and expand the Hybrid Drug model across multiple therapeutic areas.”
Ziv Kop, managing partner at O.G. Venture Partners Israel, said Remepy is “pioneering a new category of medicine” by combining biotechnology, AI and digital health.
“With compelling clinical data, growing regulatory momentum and strong validation from leading pharmaceutical partners, we believe Hybrid Drugs have the potential to transform patient care,” Kop said.
Dr. Eyal Ben Ami, scientific lead at M Ventures, said the investment reflects the growing role of AI in health care and drug delivery.
“Remepy’s pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines,” he said. “We look forward to advancing it across multiple drug classes and disease areas.”